Live news related to AB SCIENCE stock (FR0010557264): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on AB SCIENCE mainly cover M&A activity, guidance and outlook et share price moves. The stock trades at €0,54 on Euronext Paris, down 1,28% at the last update. This page lists the articles published on AB SCIENCE stock to track the share price, company announcements and any item likely to influence market perception.
The Paris-based biotech company rebounds sharply during trading and ranks among the best performers on the market. This renewed activity comes ahead o…
In a press release published on October 12, 2026, the Parisian pharmaceutical company announced the holding of a web conference intended to present it…
The Parisian biotech company specialized in oncology and inflammatory diseases recorded the steepest decline across the entire CAC All Shares index on…
The Paris-based laboratory has provided an update on its clinical programs and financial calendar following a good clinical practice inspection conduc…
AB Science has announced the discontinuation of three non-priority clinical studies of masitinib, in order to focus its resources on two programs: AB8…
AB Science restructured its governance on July 7, 2026, by appointing Stéphane Ledermann as the CEO and Chairman, a shareholder for over fourteen year…
AB Science announced on Wednesday the successful completion of a private placement of €2.3 million with institutional investors. This capital increase…
AB Science announced on Monday the completion of stage 3 of its phase 1 clinical trial evaluating the combination of AB8939 and venetoclax in the trea…
AB Science announced on Wednesday that it has been granted a U.S. patent protecting masitinib until May 2042 for the treatment of hormone-resistant me…
AB Science announced on Tuesday that new analyses of its phase 3 trial on masitinib in amyotrophic lateral sclerosis will be presented at the 2026 ann…
